Head of UNMC Fetal Cell Research Team Will Study in Israel for Eight Months:


UNMC Scientist, Dr. Howard Gendelman, Receives Prestigious

Fulbright Award

Howard Gendelman, M.D., David T. Purtilo Distinguished Professor of

Pathology and Microbiology and director of the Center for Neurovirology

and Neurodegenerative Diseases (CNND) at the University of Nebraska Medical

Center, has been named a J. William Fulbright Research Scholar, the most

presitgious honor bestowed by the Fulbright Program.

As a Fulbright Research Scholar, Dr. Gendelman will serve as a scientific

ambassador for the United States, leaving later this year to study nerve

regeneration for eight months at the Weizmann Institute of Science in Israel.

The Weizmann Institute is considered one of the leading centers in the

world in neurosciences research especially investigation into how nerve

cell damage in the spinal cord and brain can be regenerated.

The Fulbright Program was established in 1946, at the end of World War

II, by Sen. Fulbright of Arkansas. The purpose of the program is to increase

mutual understanding between the U.S. and other countries through the exchange

of persons, knowledge and skills. Participants, who are chosen for their

leadership potential, exchange ideas and embark on joint ventures of importance

to the general welfare of the world’s inhabitants. The U.S. Department

of State is the principal administrator of the program.

Dr. Gendelman is the first UNMC faculty member to be selected as a Fulbright

Research Scholar since John Connolly, M.D., former chairman of the orthopedic

surgery department, went to Australia for seven months of study in 1982.

Dr. Gendelman joined the UNMC faculty in 1993 and has focused his research

on neurodegenerative brain diseases.  He has made important contributions

to understanding how inflammatory brain responses lead to neurodegeneration

and dementia. A group of UNMC scientists under Dr. Gendelman’s direction

discovered the means to reverse AIDS-related dementia. The disease previously

led to certain death within weeks to months after the onset of neurological

symptoms.

“It’s truly a great honor for Dr. Gendelman to be selected as a Fulbright

Research Scholar, and it’s likewise a very positive reflection on UNMC.

This is one of the most competitive awards in science. It’s a recognition

that goes to only the best and brightest of individuals,” said Harold M.

Maurer, M.D., UNMC chancellor. “This is certainly another strong validation

of the outstanding research being done by  Dr. Gendelman and his colleagues.

We’re confident that he’ll be able to apply his learning at the Weizmann

Institute and bring technology back to benefit all Nebraskans.”

“Being selected a Fulbright Research Scholar is a humbling experience,”

Dr. Gendelman said. “It may be an individual honor, but there is no way

I would have gotten it without the support of the 29 researchers and two

administrators in the CNND. I also want to express my sincere appreciation

to the many University of Nebraska faculty, administrators and students

who have stood behind me and been so supportive of my research.”

The CNND’s research is considered to be among the world’s best in neuroimmunology,

said two of Dr. Gendelman’s nominators for the Fulbright Award. The research

seeks to understand how brain cells are damaged and to find ways to regenerate

these damaged brain cells in neurodestructive diseases such as Alzheimer’s

disease, Parkinson’ disease, multiple sclerosis and AIDS-related dementia.

A small portion of Dr. Gendelman’s research involves the use of fetal

brain cells from elective abortions and has been the center of a major

controversy in the state since last November.

To qualify as a Fulbright Research Scholar, individuals must be nominated

by two leading experts from institutions other than their own. Dr. Gendelman

was nominated by William C. Mobley, M.D., Ph.D., professor and chairman

of the Stanford University Medical Center Department of Neurology and Neurological

Sciences, and Peter G. E. Kennedy, M.D., professor and head of the University

of Glasgow Department of Neurology.

In his nomination, Dr. Mobley wrote: “In Dr. Gendelman and his staff,

UNMC has a genuine champion for discovering both the biological basis for

Alzheimer’s disease and its treatment. I know of no other group in the

United States that has such a clear view of the role that brain immune

function may play in the pathogenesis of Alzheimer’s disease.”

In going to Israel, Dr. Gendelman will be collaborating with Michal

Schwartz, M.D., of the Weizmann Institute, who is recognized as a world

authority on spinal cord regeneration. Dr. Schwartz has been able to use

immune cells from the spinal cord and brain to allow an adult rat with

a severed spinal cord to regain partial motor function. Dr. Gendelman is

using these same cells in his research.

In his nomination, Dr. Kennedy wrote: “I believe it is very clear that

Dr. Gendelman’s considerable expertise in macrophage biology and pathology

would be of great value to Dr. Schwartz’s research program and this combination

of talent may well lead to innovative and productive results.”

A prodigious researcher, Dr. Gendelman has had more than 160 articles

published in scientific journals, edited three books and served on the

editorial board or as editor of six biomedical research journals. He has

been an invited lecturer for more than 200 scientific seminars and symposia.

A 1979 graduate of Pennsylvania State University College of Medicine, he

was honored in 1999 as a Pennsylvania State University Distinguished Alumni.

“The Fulbright recognition is truly an incredible opportunity,” Dr.

Gendelman said. “The concepts for brain regeneration are the same as for

spinal cord regeneration. I’m going to the Mecca for spinal cord regeneration

and studying with the best in the business. Dr. Schwartz and I are trying

to come up with some answers for diseases of the brain and the spine with

no cures that leave people in nursing homes and wheelchairs. Hopefully,

Nebraska will be a better place because of the ideas and technology I will

bring back.”

Sen. Fulbright, who died in 1995 at the age of 89, was elected to the

U.S. House of Representatives in 1942 and to the U.S. Senate in 1944. He

served five terms in the Senate from 1944 to 1974.

UNMC is the only public academic health science center in the state.

Through its commitment to research, education, outreach and patient care,

UNMC has established itself as one of the country’s leading centers for

cancer research and treatment, solid organ transplantation and arthritis.

During the past year, nearly $31 million in research grants and contracts

were awarded to UNMC scientists, and UNMC’s funding from the National Institutes

of Health increased by 28 percent, going from $16.2 million to $20.7 million.

UNMC’s educational programs are responsible for training more health professionals

practicing in Nebraska than any other institution.